

# SUBJECT INDEX VOLUME 16

- A**
- ACTH, cocaine and, 399
- Addiction, cocaine, 77
- ADHD. *See* Attention deficit/hyperactivity disorder (ADHD)
- $\alpha_2$ -Adrenoceptor antagonist, gender and, 298
- Adrenocorticotrophic hormone (ACTH). *See* ACTH
- $\beta$ -Adrenoreceptors, alcoholism, panic disorder, and, 69
- Affective disorders, lithium and, 408
- Aggression, platelet 5-HT<sub>2A</sub> receptors and, 211
- Aging, somatostatin effects on sleep, 339
- Alcoholism,  $\beta$ -adrenoreceptors in panic disorder and, 69
- Alpha-ethyltryptamine (AET), effects on prepulse inhibition (PPI) and startle habituation, 246
- Alprazolam
- CYP2C19 status and, 8
  - 5-mephenytoin 4-hydroxylation and, 8
  - smoking and, 8
- Alzheimer's disease, thiopental and, 269
- Amino acids, effects on tardive dyskinesia with schizophrenia, 136
- d-Amphetamine, opiate-dopamine interactions, 147
- Amphetamines, neonatal hippocampal lesion-induced behavioral hyperresponsiveness and, 259
- Anticonvulsants, valproic acid, 238
- Antipsychotic drugs, effects on dopamine D<sub>2</sub> and 5-HT<sub>2</sub> receptors, 1
- AP-1, valproic acid and, 238
- Attention, seligiline in attention deficit/hyperactivity disorder (ADHD) adults, 276
- Attention deficit/hyperactivity disorder (ADHD), selegiline in adults, 276
- Atypical antipsychotic drugs, olanzapine effects on dopamine D<sub>2</sub> and 5-HT<sub>2</sub> receptors, 1
- B**
- Beta activity, thiopental in dementia and, 269
- Bipolar disorder
- lithium and, 325
  - valproic acid and, 238
- Blood platelets, serotonin receptors and, 285
- Blood pressure, serotonin receptors and, 285
- Body mass index, serotonin receptors and, 285
- Body weight, serotonin receptors and, 285
- Brain
- lithium and carbamazepine effects on rat, 25
  - ventricular brain ratio, schizophrenia in drug-naive patients and, 51
- C**
- c-fos, binding assays, 238
- c-jun, binding assays, 238
- cAMP responsive element binding protein (CREB), valproic acid and, 238
- Cannabinoids, prefrontal cortical catecholaminergic utilization, spatial working memory, and, 426
- Carbamazepine, thyroid hormone metabolism and, 25
- Catalepsy, atypical neuroleptics and, 93, 111, 114, 116, 123
- Catecholamines, selective attention and, 202
- CCK, social phobia and, 229
- Cell membrane, lithium in bipolar disorder and, 325
- Cerebrospinal fluid (CSF), levels in transforming growth factors with schizophrenia, 83
- Chemical models, social phobia and, 229
- m-Chlorophenylpiperazine (m-CCP), premenstrual dysphoric disorder (PMDD) and, 346
- Cholecystokinin (CCK), social phobia and, 229
- Cholinergic, lithium and basal and stimulated c-fos mRNA expression in rat brain, 408
- Clonidine, selective attention and, 202
- Clozapine
- dopamine D<sub>2</sub> and D<sub>4</sub> receptors and, 93, 111, 114, 116, 123
  - prefrontal cortical cognitive defects and, 433
- Cocaine
- corticosterone blockade and, 156
  - gender and cocaine-induced HPA axis activation, 399
  - opiate-dopamine interactions, 147
  - sensitization, 77
- Cognition
- cannabinoids and, 426
  - cholinergic, dopaminergic, and serotonergic blockade effects, 15
  - clozapine and, 433
- Contraceptives, oral, serotonin receptors and, 285
- Cortical development, schizophrenia and, 385
- Corticosterone, cocaine and, 156
- Cortisol, D-cycloserine and, 317
- CREB, valproic acid and, 238
- D-Cycloserine, behavioral and neuroendocrine effects, 317
- CYP2C19 status, alprazolam and, 8
- Cytochrome P450
- alprazolam and, 8
  - serotonin receptors and, 285
- D**
- Deiodinases, lithium and carbamazepine effects, 25
- Delayed alteration, cannabinoids and, 426
- Delayed response task, clozapine and, 433
- Depression
- diabetes and, 183
  - major, selective serotonin reuptake inhibitors (SSRI) effects on 5-HT<sub>1A</sub> agonists, 333
  - serotonin receptors in suicide victims, 162
  - tryptophan depletion and, 294
  - valproic acid and, 238
- Diabetes, effects on dopamine and serotonin receptors, 183
- Dopamine
- clozapine and, 433
  - neuronal circuits and, 385
  - psychosis, 191
  - schizophrenia and, 61
- Dopamine D<sub>1</sub> receptors, neonatal hippocampal lesions and, 259
- Dopamine D<sub>2</sub> receptors
- naloxone-precipitated withdrawal with opiate-dependence and, 174
  - neonatal hippocampal lesions and, 259
  - neuronal circuits and, 375
  - olanzapine effects on 5-HT<sub>2</sub> and, 1
- Dopamine D<sub>3</sub> receptors, neuronal circuits and, 375
- Dopamine D<sub>4</sub> receptors
- atypical neuroleptics and, 93, 111, 114, 116, 123
  - neuronal circuits and, 375
- Dopamine receptors, streptozotocin-induced diabetes effects, 183
- Dopaminergic, lithium and basal and stimulated c-fos mRNA expression in rat brain, 408
- Droperidol, selective attention and, 202
- Drug-naive patients, schizophrenia in, 51
- Drug therapy, bipolar disorder and, 325
- E**
- EEG, thiopental in dementia and, 269
- EEG sleep, schizophrenia in drug-naive patients and, 51
- ELISA, transforming growth factors and schizophrenia, 83
- Event-related potential (ERP), selective attention and, 202
- Eye movement, risperidone and haloperidol effects, 217
- F**
- Females, cocaine-induced HPA axis activation and, 399
- First-episode schizophrenia, m-chlorophenyl-piperazine vs. methylphenidate, 61
- <sup>18</sup>F-Fluoro-deoxyglucose (FDG), gender and idazoxon effects, 298
- [F-18]-Fluorodeoxyglucose (FDG), psilocybin model of psychosis, 357

**Fluoxetine**  
 alpha-ethyltryptamine (AET) effects on  
 startle habituation and, 246  
 effects on extracellular norepinephrine in  
 hippocampus, 419  
 premenstrual dysphoric disorder (PMDD)  
 and, 346  
**Follicular phase, fluoxetine and, 346**  
**c-fos mRNA expression, lithium and, 408**  
**Fuller, Ray, in memoriam, 256**

## G

**Gender, cocaine-induced HPA axis**  
 activation and, 399  
**GHRH, somatostatin and sleep effects in**  
 elderly and, 339  
**Growth hormone-releasing hormone**  
 (GHRH). *See* GHRH

## H

**Habituation, alpha-ethyltryptamine (AET)**  
 and, 246  
**Haloperidol**  
 cognitive and behavioral effects, 15  
 effects on dopamine and serotonin  
 receptors, 183  
 saccadic eye movements and, 217  
**Heterogeneity, dopamine psychosis, 191**  
**Hippocampus**  
 dopamine receptors and, 259  
 serotonin receptors in suicide victims with  
 depression and, 162  
**Homovanillic acid, psychosis, 191**  
**HPA axis activation, gender and cocaine-**  
 induced, 399  
**5-HT agonists, alpha-ethyltryptamine**  
 (AET) effects on startle habituation and,  
 246  
**5-HT<sub>1A</sub> agonists, selective serotonin**  
 reuptake inhibitors (SSRI) effects, 333  
**5-HT<sub>2</sub> receptors**  
 olanzapine effects on dopamine D<sub>2</sub> and, 1  
 psilocybin model of psychosis, 357  
**Humans**  
 positron emission tomography study of  
 5-HT<sub>2</sub> and dopamine D<sub>2</sub> receptor  
 occupancy, 1  
 psilocybin model of psychosis, 357  
**Hyperactivity, seligiline in attention deficit/**  
 hyperactivity disorder (ADHD) adults,  
 276  
**Hypothalamo-pituitary-adrenal (HPA) axis.**  
*See* HPA axis

## I

**Idazoxan, gender and responses to  $\alpha_2$ -**  
 adrenoceptor blockade, 298  
**Imidazoline, gender and responses to  $\alpha_2$ -**  
 adrenoceptor blockade, 298  
**In memoriam, Winokur, George, 438**  
**In vivo microdialysis, fluoxetine effects on**  
 extracellular norepinephrine in  
 hippocampus, 419  
**Ion transport, lithium in bipolar disorder**  
 and, 325

## L

**Latent inhibition, neuroleptic-induced**  
 enhancement, 42  
**LH, D-cycloserine and, 317**

**Lithium**  
 basal and stimulated c-fos mRNA  
 expression in rat brain and, 408  
 bipolar disorder and, 325  
 thyroid hormone metabolism and, 25  
**Locomotion**  
 corticosterone blockade effects on cocaine,  
 156  
 dopaminergic agonists and antagonists  
 and, 259  
 opiate-dopamine interactions and, 147  
**Locus coeruleus, fluoxetine effects on**  
 extracellular norepinephrine, 419  
**Luteal phase, fluoxetine and, 346**  
**Luteinizing hormone (LH). *See* LH**  
**Lysergic acid diethylamide, serotonin**  
 receptors and, 285

## M

**M-chlorophenyl-piperazine, schizophrenia**  
 and methylphenidate vs., 61  
**Major depression, selective serotonin**  
 reuptake inhibitors (SSRI) effects on  
 5-HT<sub>1A</sub> agonists, 333  
**Mania, valproic acid and, 238**  
**MAOI, attention deficit/hyperactivity**  
 disorder (ADHD) and, 276  
**Memory, cannabinoids and, 426**  
**Menstrual cycle, serotonin receptors and,**  
 285  
**Metabolism, alprazolam and, 8**  
**Metergoline, cognitive and behavioral**  
 effects, 15  
**N-Methyl-D-Aspartate (NMDA) receptors.**  
*See* NMDA receptors  
**3,4-Methylenedioxy-N-**  
 methylamphetamine (MDMA), alpha-  
 ethyltryptamine (AET) vs., 246  
**Methylphenidate, schizophrenia and**  
 m-chlorophenyl-piperazine vs., 61  
**Metyrapone, corticosterone blockade effects**  
 on cocaine and, 156  
**Microdialysis, in vivo, fluoxetine effects on**  
 extracellular norepinephrine in  
 hippocampus, 419  
**Monoamine metabolites, attention deficit/**  
 hyperactivity disorder (ADHD) and,  
 276  
**Monoamines, prefrontal cortical**  
 catecholaminergic utilization, spatial  
 working memory, and, 426  
**Morphine, opiate-dopamine interactions,**  
 147

## N

**Naloxone, dopamine D<sub>2</sub> receptors in opiate-**  
 dependence and, 174  
**Neonatal lesions, dopamine receptors and,**  
 259  
**Neuroleptic response, homovanillic acid**  
 psychosis and, 191  
**Neuroleptics**  
 dopamine D<sub>2</sub> and D<sub>4</sub> receptors and, 93,  
 111, 114, 116, 123  
 latent inhibition and, 42  
**Neuronal circuits, schizophrenia and, 375,**  
 385  
**Neurotoxins, neonatal hippocampal lesions**  
 and, 259  
**NMDA receptors, behavioral and**  
 neuroendocrine effects, 317  
**Norepinephrine, fluoxetine effects on**  
 extracellular, 419

**Nucleus accumbens, opiate-dopamine**  
 interactions and, 147

## O

**Obsessive compulsive disorder (OCD),**  
 alpha-ethyltryptamine (AET) and, 246  
**Olanzapine, effects on dopamine D<sub>2</sub> and**  
 5-HT<sub>2</sub> receptors, 1

## P

**P3, catecholamine transmission and, 202**  
**Panic, pentagastrin and, 229**  
**Panic disorder,  $\beta$ -adrenoreceptors in**  
 alcoholism and, 69  
**Parkinsonism, atypical neuroleptics and, 93,**  
 111, 114, 116, 123  
**Pentagastrin, social phobia and, 229**  
**PET. *See* Positron emission tomography**  
 (PET)  
**Pharmacology**  
 M-chlorophenyl-piperazine, 61  
 methylphenidate, 61  
**Phenylalanine, effects on tardive dyskinesia**  
 with schizophrenia, 136  
**Pindolol, effects on 5-HT<sub>1A</sub> agonists for**  
 antidepressant response, 333  
**Plasma monoamines, attention deficit/**  
 hyperactivity disorder (ADHD) and,  
 276  
**Platelet 5-HT<sub>2A</sub> receptors, effects with**  
 personality disorder, 211  
**Positron emission tomography (PET)**  
 dopamine D<sub>2</sub> receptors in opiate-  
 dependence and, 174  
 gender and  $\alpha_2$ -adrenoceptor blockade,  
 298  
 5-HT<sub>2</sub> and dopamine D<sub>2</sub> receptor  
 occupancy, 1  
 psilocybin model of psychosis, 357  
**Prefrontal cortex**  
 cannabinoids and, 426  
 clozapine and, 433  
 schizophrenia and, 385  
 serotonin receptors in suicide victims with  
 depression and, 162  
**Prepulse inhibition (PPI), alpha-**  
 ethyltryptamine (AET) and, 246  
**Probes, M-chlorophenyl-piperazine vs.**  
 methylphenidate in schizophrenia, 61  
**Processing negativity, catecholamine**  
 transmission and, 202  
**Psilocybin, psychosis model, 357**  
**Psychomimetics, prefrontal cortical**  
 catecholaminergic utilization, spatial  
 working memory, and, 426  
**Psychomotor effects, corticosterone**  
 blockade effects on cocaine, 156  
**Psychopathology, psilocybin model of**  
 psychosis, 357  
**Psychosis**  
 cocaine, 77  
 dopamine, 191  
 psilocybin model, 357  
**Pyramidal neurons, schizophrenia and, 385**

## R

**Rapid eye movement latency, schizophrenia**  
 in drug-naïve patients and, 51  
**Rats**  
 lithium and basal and stimulated c-fos  
 mRNA expression, 408  
 lithium and carbamazepine effects, 25

neuroleptic-induced enhancement of  
latent inhibition, 42  
Receptors, serotonin, binding variability,  
285  
Relapse  
cocaine addiction, 77  
former depressed patients and  
tryptophan depletion, 294  
REM sleep, elderly and somatostatin, 339  
Risperidone, saccadic eye movements and,  
217

## S

S-mephenytoin 4-hydroxylation,  
alprazolam and, 8  
Saccades, risperidone and haloperidol  
effects, 217  
Schizophrenia  
clozapine and, 433  
D-cycloserine and, 317  
dopamine psychosis and, 191  
dopamine receptors and, 375, 385  
EEG sleep in drug-naïve patients, 51  
m-chlorophenyl-piperazine vs.  
methylphenidate, 61  
phenylalanine effects with tardive  
dyskinesia and, 136  
premenstrual dysphoric disorder (PMDD)  
and, 346  
psilocybin model of psychosis, 357  
transforming growth factors and, 83  
Scopolamine, cognitive and behavioral  
effects, 15  
Seasons, serotonin receptors and, 285  
Selective attention, catecholamine  
transmission and, 202  
Selective serotonin reuptake inhibitors  
(SSRI), effects on 5-HT<sub>1A</sub> agonists for  
antidepressant response, 333  
Seligiline, attention deficit/hyperactivity  
disorder (ADHD) adults and, 276

Sensitization  
cocaine, 77  
opiate-dopamine interactions, 147  
Serotonin  
aggression in personality disorder and,  
211  
alpha-ethyltryptamine (AET) effects on  
startle habituation and, 246  
schizophrenia and, 61  
tryptophan depletion in former depressed  
patients and, 294  
Serotonin receptors  
streptozotocin-induced diabetes effects,  
183  
suicide victims with depression and,  
162  
Serotonin<sub>2</sub> receptors, atypical neuroleptics  
and, 93, 111, 114, 116, 123  
Sex characteristics,  $\alpha_2$ -adrenoceptor  
blockade and, 298  
Side effects, risperidone and haloperidol,  
217  
Signal transduction, lithium and basal and  
stimulated c-fos mRNA expression in  
rat brain, 408  
Sleep  
elderly and somatostatin, 339  
slow wave, schizophrenia in drug-naïve  
patients and, 51  
Sleep endocrinology, elderly and  
somatostatin, 339  
Slow wave sleep, schizophrenia in drug-  
naïve patients and, 51  
Smoking, alprazolam and, 8  
Social interaction, pentagastrin and, 229  
Somatostatin, sleep effects in elderly, 339  
Startle habituation, alpha-ethyltryptamine  
(AET) and, 246  
Streptozotocin, -induced diabetes, effects on  
dopamine and serotonin receptors,  
183  
Stress  
clozapine and, 433

fluoxetine effects on extracellular  
norepinephrine in hippocampus and,  
419  
lithium and basal and stimulated c-fos  
mRNA expression in rat brain, 408  
Suicide, serotonin receptors and, 162  
Switching, neuroleptics, 42

## T

Tardive dyskinesia  
diabetes and, 183  
phenylalanine in schizophrenia with, 136  
Thiopental, Alzheimer's type dementia and,  
269  
Thyroid hormones, lithium and  
carbamazepine effects, 25  
Transcription factors, valproic acid and, 238  
Transforming growth factors, schizophrenia  
and, 83  
Tricyclic antidepressants, effects on 5-HT<sub>1A</sub>  
agonists for antidepressant response,  
333  
Tryptophan depletion, former depressed  
patients and, 294

## V

Valproic acid, AP-1 transcription factor  
DNA binding activity and, 238  
Vascular dementia, thiopental and, 269  
Ventricular brain ratio, schizophrenia in  
drug-naïve patients and, 51

## W

Winokur, George, in memoriam, 438  
Withdrawal, dopamine D<sub>2</sub> receptors in  
opiate-dependence and, 174